ArticleJournal of ovarian research2025
SLC4A11 is a targetable marker correlated with therapeutic responses in ovarian cancer.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Role of solute carrier family 7 member 7 in cancer: opportunities for tumor microenvironment research.Journal for immunotherapy of cancer · 2026Review
- Ammonia signaling network: the intersection of tumor metabolism, epigenetics, and metastasis.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSolute carrier family 4 member 11 (SLC4A11) is involved in borate homeostasis, metabolism reprogramming, cell growth, and cell adhesion. However, the biological function of SLC4A11 in ovarian cancer (OC) is still unclear. This study explores the anti-tumor and biological activities of SLC4A11 in OC.
methodsThe expression and function of SLC4A11 were evaluated in human OC cells and xenograft mice. SLC4A11 expression was evaluated using data from the TCGA-OV, GTEx, and GEO datasets. The genetic status of SLC4A11 was analyzed by the cBioPortal database. The data of expressional abundance, immunochemistry, and immunofluorescence were analyzed through the HPA database. The correlation between SLC4A11 and immune responses was analyzed with the CIBERSORT database, whereas therapeutic responses were analyzed with the CellMiner database.
resultsSLC4A11 was found to be highly expressed in OC tissues/cells and had a relationship with an unfavorable prognosis in patients with OC. The overexpressed SLC4A11 promoted OC cell proliferation, migration, and invasion. Reducing SLC4A11 caused the cell cycle arrest at the G0/G1 phase and triggered apoptosis. The in vivo study with a xenographic model revealed that the knockdown of SLC4A11 suppressed tumor growth. Subsequent bioinformatics analyses revealed that SLC4A11 expression was associated with immune responses and therapeutic drug sensitivity.
conclusionsThese findings have illustrated the oncogenic role of SLC4A11 in OC. SLC4A11 is overexpressed and is correlated with poor prognosis in OC. SLC4A11 may be a targetable biomarker and has a potential value of application in treating patients with OC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.